Tango Therapeutics,(TNGX) Investor Presentation - Slideshow

First clinical trial ongoing and three IND filings planned for 2023 • TNG462 phase 1/2 trial initiation expected mid-2023 - a next generation MTA-cooperative PRMT5 inhibitor • TNG348 IND filing mid-2023 - a USP1 inhibitor for BRCA1/2 mutant and other HRD+ cancers A strong strategic partnership with Gilead | 5 Gilead optioned and licensed targets not listed | 6 | 7 OTHER (PRMT5) | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------- ...